CD19 and acute lymphoblastic leukemia: To date, three CD19-targeted CAR T cell products have been FDA- and EMA-approved for ALL—tisagenlecleucel, brexucabtagene autoleucel, and obecabtagene autoleucel—based on the results of the ELIANA [187], ZUMA-3 [188], and FELIX [189] studies, respectively.